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There is currently considerable interest in the relationship between variation in genes that are involved in the folate-
homocysteine metabolic axis and the risk of spina bifida. The evaluation of this relationship is, however, complicated
by the potential involvement of both the maternal and the embryonic genotype in determination of disease risk.
The present study was designed to address questions regarding both maternal and embryonic genetic risk factors
for spina bifida by use of the two-step transmission/disequilibrium test. Analysis of data on variants of two genes
involved in homocysteine remethylation/methionine biosynthesis—methionine synthase (MTR) A2756G and me-
thionine synthase reductase (MTRR) A66G—provided evidence that both variants influence the risk of spina bifida
via the maternal rather than the embryonic genotype. For both variants, the risk of having a child with spina bifida
appears to increase with the number of high-risk alleles in the maternal genotype: MTR ( , 95% CIR p 2.161
0.92–5.06; , 95% CI 0.87–49.67) and MTRR ( , 95% CI 1.05–3.99; , 95% CIR p 6.58 R p 2.05 R p 3.152 1 2
0.92–10.85). These findings highlight the importance of considering both the maternal and embryonic genotype
when evaluating putative spina bifida susceptibility loci.
Maternal genetic effects occur when a genetically me-
diated maternal phenotype influences the phenotype of
offspring. Such effects are independent of the alleles con-
tributed by the mother to her offspring and are, there-
fore, genetic only with respect to the mother. With re-
spect to offspring, maternal genetic effects behave as
environmental risk factors. Studies in animals indicate
that maternal genetic effects can contribute to the risk
of specific malformations among offspring (see, e.g.,
Trasler and Trasler 1984; Gilliam et al. 1997). The ter-
atogenic effect of untreated maternal phenylketonuria
(MIM 261600) provides a classic example of a maternal
genetic effect that influences human development (Ma-
bry et al. 1963).
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Research indicating that the risk for neural tube de-
fects (NTD [MIM 601634, MIM 601635]) may be re-
lated to functional variants of genes involved in the fo-
late-homocysteine metabolic axis has spurred interest in
maternal genetic effects, because such variants could in-
fluence the risk of NTD through the maternal, the em-
bryonic, or both the maternal and embryonic genotypes.
Case-control studies comparing both subjects with NTD
and their mothers to control subjects have provided ev-
idence that the maternal genotypes for 5,10 methyle-
netetrahydrofolate reductase (MTHFR [MIM 607093])
and methionine synthase reductase (MTRR [MIM
602568]) are associated with the risk of NTD (White-
head et al. 1995; van der Put et al. 1996; Christensen
et al. 1999; Wilson et al. 1999). However, on the basis
of the data available from such studies, it is not possible
to determine whether these associations reflect the trans-
mission of maternal alleles that exert an effect via the
embryonic genotype, maternal genetic effects, or a com-
bination of both maternal and embryonic effects (Posey
et al. 1996).
Two family-based approaches for assessing the rela-
tionship between disease risk and both maternal and
offspring genotypes have recently been proposed (Mitch-
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ell 1997; Weinberg et al. 1998; Wilcox et al. 1998). The
two-step transmission-disequilibrium test (TDT) (Mitch-
ell 1997) uses data from family trios consisting of a
proband and both parents (proband trios) and from trios
consisting of the mothers of probands and bothmaternal
grandparents (mother trios). The relationship between
proband genotype and risk of disease is assessed in the
usual way (Spielman et al. 1993), by evaluating the
transmission of alleles from heterozygous parents to
their affected offspring. The relationship between ma-
ternal genotype and risk of having an affected child is
assessed by evaluating the transmission of alleles from
heterozygous maternal grandparents of affected individ-
uals to the mothers of those individuals. Therefore,when
the proband’s genotype is assessed, “being affected with
an NTD” is the phenotype of interest, whereas, when
the maternal genotype is assessed, “having a child with
an NTD” is the phenotype on which the TDT is per-
formed. Both steps in the two-step TDT provide tests of
linkage in the presence of linkage disequilibrium and are
unbiased by population subdivision or admixture (Ew-
ens and Spielman 1995).
An alternative approach applies log-linear modeling
to data derived from only proband trios (Weinberg et
al. 1998; Wilcox et al. 1998). This approach character-
izes each proband trio according to the number of high-
risk alleles (0, 1, or 2) in the genotypes of the father,
mother, and child. Asymmetry in the distribution of the
proband genotypes, conditional on parental genotypes,
permits estimation of the offspring genotypic effects. The
likelihood-ratio test (LRT) comparing models with and
without parameters characterizing the offspring geno-
typic effects is a generalization of the TDT. Conse-
quently, this LRT provides a test of linkage in the pres-
ence of linkage disequilibrium and is unbiased by
population structure or admixture (Weinberg et al.
1998). Estimation of maternal genotypic effects is based
on asymmetry in the distribution of reciprocal mating
types. The LRT comparing models with and without
parameters characterizing the maternal genotypic effects
provides a test of association only and is, therefore, sub-
ject to bias resulting from population structure or ad-
mixture (Wilcox et al. 1998).
The present study was designed to address questions
regarding both maternal and offspring genetic risk fac-
tors for spina bifida by use of the two-step TDT. In this
paper, we describe the results of our analyses of data for
variants in two genes involved in homocysteine reme-
thylation/methionine biosynthesis: methionine synthase
(MTR [MIM 156570]), A2756G (D919G), and MTRR
A66G (I22M). A potential role for these genes in the
etiology of spina bifida [MIM 182940] is suggested by
the metabolic profile (i.e., relatively elevated homocy-
steine and relatively low vitamin B12 and red blood cell
folate levels [Mills et al. 1995; Lucock et al. 1998, 2000])
of women who have had a child or pregnancy affected
with an NTD. Neither embryonic (Morrison et al. 1997;
Christensen et al. 1999; Shaw et al. 1999; Johanning et
al. 2000) nor maternal (Morrison et al. 1997; Christen-
sen et al. 1999) genetic effects on NTD risk have been
demonstrated for the MTR A2576G variant. However,
in a small study, MTRR A66G genotypes appeared to
be associated with spina bifida in both probands and
their mothers (Wilson et al. 1999).
As part of an ongoing study of the genetics of spina
bifida (i.e., a defect of the caudal neural tube), families
( ) that included at least one affected (i.e., withnp 209
meningocele, meningomyelocele, or myelocele) member
were ascertained through several sources: the Spina Bi-
fida Program ( ) and the Center for Fetal Di-np 113
agnosis and Therapy (np 35) at the Children’s Hospital
of Philadelphia; the Spinal Dysfunction Clinic at the Al-
fred I. duPont Hospital for Children, Wilmington
( ); advertisements in professional and supportnp 51
group newsletters ( ); and self referral ( ).np 9 np 1
Blood and/or buccal samples were obtained from the
family member(s) affected with spina bifida (i.e., the pro-
band) and his or her (their) parents, sibs, and maternal
grandparents. The study protocol was approved by the
Institutional Review Boards of The University of Penn-
sylvania School of Medicine and each of the participat-
ing hospitals. Informed consent—and assent, when ap-
propriate—were obtained for all study subjects.
Genomic DNAwas extracted fromwhole blood, using
GENERATION Capture Columns (Gentra Systems), or
from buccal samples, using a published protocol (Walker
et al. 1999). The MTR A2756G and MTRR A66G ge-
notyping was performed using heteroduplex generators
described elsewhere (Barbaux et al. 2000; Gaughan et
al. 2001). Genotypes were read independently by two
individuals and were interpreted blind to the identity of
the samples. Repeat genotyping assays were performed
on all samples that gave inadequate product or equivocal
genotypes.
Associations between maternal and offspring MTR
and MTRR genotypes and spina bifida were assessed
using the two-step TDT (Mitchell 1997). Since the TDT
is invalid when data from unambiguous parent-child dy-
ads are included and data from ambiguous dyads are
excluded from analysis (Curtis and Sham 1995), only
data from complete trios were included in these analyses.
Families that included more than one individual with
spina bifida contributed one trio for each affected in-
dividual, since the TDT remains a valid test of linkage
when there is more than one affected individual per fam-
ily (Spielman and Ewens 1996). These analyses were
carried out using the TDT-STDT program (version 1.1).
Associations between maternal and offspring MTR
and MTRR genotypes and spina bifida were also as-
sessed using a log-linear approach. To assess the effects
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Table 1
Summary of the MTR and MTRR Data and Results Obtained Using the TDT and LRT
VARIANT
MTR A2756G MTRR A66G
Proband Trios Mother Trios Proband Trios Mother Trios
No. of complete trios (no. with one
heterozygous parent, no. with two
heterozygous parents)
84 (37, 9) 22 (7, 4) 117 (67, 29) 41 (26, 6)
No. of parent-child dyads (F-C, M-C) 48 (5, 43) 36 (12, 24) 42 (3, 39) 27 (6, 21)
No. of informative transmissionsa 55 15 125 38
No. (%) of informative transmissions of
designated high-risk allele
30 (54.6) 13 (86.7) 58 (46.4) 25 (65.8)
TDT: (P value)2x1 0.46 (0.50) 8.07 (0.004) 0.65 (0.42) 3.79 (0.05)
R1 (95% CI)
b 1.18 (0.69–1.98) 2.16 (0.92–5.06) 0.88 (0.56–1.39) 2.05 (1.05–3.99)
R2 (95% CI)
b 1.10 (0.34–3.50) 6.58 (0.87–49.67) 0.70 (0.36–1.36) 3.15 (0.92–10.85)
Generalized LRT: (P value)2x2 0.33 (0.85) 4.59 (0.10) 1.09 (0.58) 5.18 (0.08)
Linearized LRT: (P value)c2x1 … 4.69 (0.03) … 5.02 (0.02)
a Informative transmissions p transmissions from heterozygous parents who are members of a complete trio.
b Estimates of R1 (R2) and 95% CIs were obtained from the generalized LRT.
c The linearized LRT was a post hoc analysis that was applied only to data from mother trios.
of offspring genotype, each proband trio was charac-
terized according to the number of high-risk alleles in
the genotypes of the father (F), mother (M), and child
(C), and the following log-linear model was fitted to the
resulting count data:
ln [E(n )]p g  b I  b I  ln (w ) .F,M,C j 1 (Cp1) 2 (Cp2) F,M,C
The gj parameter serves to stratify on mating type.
and are dummy variables that take on theI I(Cp1) (Cp2)
value of 1 when and , respectively, and areCp 1 Cp 2
0 otherwise. The wF,M,C are cell weights that are: 2 for
trios consisting entirely of heterozygotes, and 1 for all
other possible combinations. The risks of spina bifida
associated with offspring genotypes including one (R1)
or two (R2) copies of the high-risk allele, relative to the
offspring genotype with no copies, were estimated by
exp(b1) and exp(b2), respectively. The significance of the
offspring genotype was assessed using the 2-df LRT com-
paring the above model to the null model in which
. The significance of the maternal genotypeb p b p 01 2
and estimates of maternal genotypic relative risks were
obtained in an analogous manner, using data from the
mother trios.
These log-linear analyses were carried out using LEM
(Vermunt 1997), a program for log-linear analysis with
missing data that uses the expectation-maximization
(EM) algorithm, as described by van den Oord and Ver-
munt (2000). Using the EM algorithm allows incomplete
trios to contribute their information to the LRT without
invalidation of the analysis, and has been shown to re-
capture much of the loss in information from incomplete
trios (Weinberg 1999; van den Oord and Vermunt
2000). Hence, data from complete trios (F-M-C) and
parent-child dyads (F-C, M-C) were included in these
log-linear analyses. In the families that included more
than one individual with spina bifida who was available
for genotyping, one individual was randomly selected
(i.e., coin flip) for inclusion in the proband trio. It is
necessary to restrict the analyses in this way to obtain
unbiased standard error estimates.
The study sample comprises 209 families that include
at least one individual affected with spina bifida. Four
of these families include an affected sib pair (np 213
affected). The results from the two-step TDT and log-
linear analyses are summarized in table 1. Briefly, MTR
A2756G genotypes were obtained for 84 proband trios,
which included 55 heterozygous parents and, hence, 55
transmissions that were informative for the TDT. The
informative transmissions included 30 (54.6%) 2756G
alleles and 25 (45.4%) 2756A alleles. The difference in
the transmission frequency of these alleles, from hetero-
zygous parents to their affected offspring, was not sta-
tistically significant.
MTR A2756G genotypes were obtained for 22
mother trios, which included 15 heterozygous maternal
grandparents of a child with spina bifida. The infor-
mative transmissions included 13 (86.7%) 2756G alleles
and only 2 (13.3%) 2756A alleles. The difference in the
frequency of transmitted alleles, from heterozygous ma-
ternal grandparents to the mothers of a child with spina
bifida, was statistically significant, suggesting that the
2756G allele should be designated as the high-risk
variant.
MTRR A66G genotypes were obtained for 117 com-
plete proband trios, which included 125 heterozygous
parents. The informative transmissions included 58
(46.4%) 66A alleles and 67 (53.6%) 66G alleles. The
difference in the transmission of these alleles, from het-
erozygous parents to their affected offspring, was not
statistically significant.
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MTRR A66G genotypes were obtained for 41 com-
plete mother trios, which included 38 heterozygous ma-
ternal grandparents. The informative transmissions in-
cluded 25 (65.8%) 66A alleles and 13 (34.2%) 66G
alleles. The difference in the transmission of alleles, from
heterozygous maternal grandparents to the mothers of
a child with spina bifida, was of borderline statistical
significance, suggesting that the 66A allele should be
designated as the high-risk variant.
Estimates of the relative increase in risk associated
with offspring genotypes having one (R1) or two (R2)
copies of the designated high-risk allele (relative to ge-
notypes with zero copies) were obtained by fitting the
full log-linear model to data from all proband trios and
dyads. Likewise, estimates of the relative increase in risk
associated with maternal genotypes having one (R1) or
two (R2) copies of the designated high-risk allele were
obtained by fitting the full log-linear model to data from
all mother trios and dyads.
The relative risk estimates for offspring MTR geno-
types were nonsignificant, and the LRT, comparing the
fit of the full model to the null model in which b1 and
b2 (i.e., the parameters defining the contribution of off-
spring genotype to risk) were set to zero, was also not
significant (table 1). In contrast, the relative risk esti-
mates for maternal MTR genotypes suggested that the
risk of having a child with spina bifida increases with
the number of high-risk alleles in the maternal genotype.
However, neither R1 nor R2 were statistically significant,
and the LRT comparing the fit of the full model to the
null model was also not significant.
The relative risk estimates for offspring MTRR ge-
notypes were also nonsignificant as was the LRT com-
paring the fit of the full model to the model in which
b1 and b2 were set to zero. In contrast, there was evidence
for an increase in risk of spina bifida in the offspring of
women with the MTRR AG and AA genotypes, relative
to the GG homozygote. The difference in fit between
the full and null model was of borderline statistical
significance.
For both MTR and MTRR, the estimates of R1 and
R2 obtained from the mother trios and dyads suggest
that the presence of at least one high-risk allele is as-
sociated with an increased risk of spina bifida in off-
spring and that this risk may be further increased when
the mother is homozygous for the high-risk allele. Sim-
ulation studies have shown that, under such a model,
the TDT may outperform the LRT (Weinberg et al.
1998). This difference in power may, at least in part,
account for the differences in the level of significance
associated with the TDT and LRT for maternal genetic
effects. A linearized LRT, which constrains R2 p R1
2
and is asymptotically equivalent to the TDT (Weinberg
et al. 1998), provided stronger evidence than the gen-
eralized LRT for maternal genetic effects at the MTR
and MTRR loci (table 1).
A recent editorial asked the question, “Why are the
genes that cause risk of human neural tube defects so
hard to find?” (Harris 2001). The answer to this ques-
tion, at least in part, may be that we are not looking for
these genes in the correct place. The results of the present
analyses provide evidence that some of the genes in-
volved in homocysteine remethylation/methionine bio-
synthesis are likely to influence the risk of spina bifida
via maternal rather than embryonic genetic effects. Stud-
ies which do not specifically address the potential role
of maternal genetic effects on the risk of spina bifida
would overlook such effects or, as in case-control studies,
would be unable to ascribe definitively the association
between offspring phenotype and maternal genotype to
maternal, embryonic, or both maternal and embryonic
genetic effects.
This study had limitations. The probands in this study
may not be representative of all embryos that develop
spina bifida. For example, our results could be biased
(e.g., an affect could have been missed) if embryos that
are homozygous for a high-risk allele are both more
likely to develop spina bifida and less likely to be live-
born. The study was also limited by the number of trios
available for study. Modest associations between pro-
band genotype and spina bifida may have been missed.
The data were also insufficient for the purposes of sub-
group analyses and for the assessment of interactions.
The primary strength of this study was its unique de-
sign, which provided data for the direct assessment of
both maternal and offspring genetic effects on spina bi-
fida risk. This report establishes the feasibility and utility
of collecting mother trios and provides the first direct
evidence that maternal genetic effects influence the risk
of spina bifida. These findings highlight the need to con-
sider maternal genetic effects in the current paradigm of
disease etiology for spina bifida and the importance of
designing future studies in a manner that will allow for
the direct assessment of maternal genetic effects.
Acknowledgments
This study was supported by grants from the Ethel Brown
Foerderer Fund for Excellence and the General Clinical Re-
search Center (M01-RR00240) of the Children’s Hospital of
Philadelphia and from the National Institutes of Health
(HD39195 andHD39081). The authors express their gratitude
to their colleagues in the Spina Bifida Program (Dr. P. Pas-
quierello and J. Melchionne) and The Center for Fetal Diag-
nosis and Therapy (Dr. N. S. Adzick, Dr. M. P. Johnson, Dr.
R. D. Wilson, L. Howell, S. Miesnik, M. Oxman, and S. Kas-
perski) at the Children’s Hospital of Philadelphia; in the Spinal
Dysfunction Clinic at the A. I. duPont Hospital for Children
(Dr. M. McManus and R. Gleeson); and to all of the families
who have enrolled in this study. The authors also thank Dr.
1226 Am. J. Hum. Genet. 71:1222–1226, 2002
E. Goldmuntz for helpful comments on an earlier version of
this manuscript.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Online Medelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/
References
Barbaux S, Kluijtmans LAJ, Whitehead AS (2000) Accurate
and rapid “multiplex heteroduplexing” method for geno-
typing key enzymes involved in folate/homocysteine metab-
olism. Clin Chem 46:907–912
Christensen B, Arbour L, Tran PLD, Sabbaghian N, Platt R,
Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P, Rozen R
(1999) Genetic polymorphisms in methylenetetrahydrofol-
ate reductase and methionine synthase, folate levels in red
blood cells, and risk of neural tube defects. Am J Med Genet
84:151–157
Curtis D, Sham PC (1995) A note on the application of the
transmission disequilibrium test when a parent is missing.
Am J Hum Genet 56:811–812
Ewens WJ, Spielman RS (1995) The transmission/disequilib-
rium test: history, subdivision, and admixture. Am J Hum
Genet 57:455–464
Gaughan DJ, Kluijtmans LAJ, Barbaux S, McMaster D, Young
IS, Yarnell JWG, Evans A, Whitehead AS (2001) The me-
thionine synthase reductase (MTRR) A66G polymorphism
is a novel genetic determinant of plasma homocysteine con-
centrations. Atherosclerosis 157:451–456
Gilliam DM,Mantle MA, Barkhausen DA, Tweden DR (1997)
Effects of acute prenatal ethanol administration in a recip-
rocal cross of C57BL/BJ and short-sleep mice: maternal ef-
fects and nonmaternal factors. Alcohol Clin Exp Res 21:
28–34
Harris MJ (2001) Why are the genes that cause risk of human
neural tube defects so hard to find? Teratology 63:165–166
Johanning GL, Tamura T, Johnston KE, Wenstrom KD (2000)
Comorbidity of 5,10-methylenetetrahydrofolate reductase
and methionine synthase gene polymorphisms and risk for
neural tube defects. J Med Genet 37:949–951
Lucock M, Daskalakis I, Briggs D, Yates Z, Levene M (2000)
Altered folate metabolism and disposition in mothers af-
fected by a spina bifida pregnancy: influence of 677crt
methylenetetradydrofolate reductase and 2756arg methio-
nine synthase genotypes. Mol Genet Metab 70:27–44
Lucock MD, Daskalakis I, Lumb CH, Schorah CJ, Levene MI
(1998) Impaired regeneration of monoglutamyl tetrahydro-
folate leads to cellular folate depletion in mothers affected
by a spina bifida pregnancy. Molecular Genetics and Me-
tabolism 65:18–30
Mabry CC, Denniston YC, Nelson TL, Son CD (1963) Ma-
ternal phenylketonuria: cause of mental retardation in chil-
dren without the metabolic defect. N Engl J Med 269:1404
Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir
DG, Scott JM (1995) Homocysteine metabolism in preg-
nancies complicated by neural tube defects. Lancet 345:
149–151
Mitchell LE (1997) Differentiating between fetal and maternal
genotypic effects, using the transmission test for linkage dis-
equilibrium. Am J Hum Genet 60:1006–1007
Morrison K, Edwards YH, Lynch SA, Burn J, Hol F, Mariman
E (1997) Methionine synthase and neural tube defects. J
Med Genet 34:958
Posey DL, Khoury MJ, Mulinare J, Adams MJ, Ou CY (1996)
Is mutated MTHFR a risk factor for neural tube defects?
Lancet 347:686–687
Shaw GM, Todoroff K, Finnell RH, Lammer EJ, Leclerc D,
Gravel RA, Rozen R (1999) Infant methionine synthase var-
iants and risk for spina bifida. J Med Genet 36:86–87
Spielman RS, Ewens WJ (1996) The TDT and other family-
based tests for linkage disequilibrium and association. Am
J Hum Genet 59:983–989
Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission
test for linkage disequilibrium: the insulin gene region and
insulin-dependent diabetes mellitus (IDDM). Am J HumGe-
net 52:506–516
Trasler DG, Trasler TA (1984) Left cleft lip predominance and
genetic similarities of L line and CL/Fr strain mice. Tera-
tology 30:423–427
van den Oord EJCG, Vermunt JK (2000) Testing for linkage
disequilibrium, maternal effects, and imprinting with
(in)complete case-parent triads, by use of the computer pro-
gram LEM. Am J Hum Genet 66:335–338
van der Put NMJ, van den Heuvel LP, Steegers-Theunissen
RPM, Trijbels FJM, Eskes TK, Mariman E, den Heyer M,
Blom HJ (1996) Decreased methylenetetrahydrofolate re-
ductase activity due to the 677CrT mutation in families
with spina bifida offspring. J Mol Med 74:691–694
Vermunt JK (1997) LEM: a general program for the analysis
of categorical data. Tilberg University, Tilberg, The
Netherlands
Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA,
Rebbeck TR (1999) Collection of genomic DNA by buccal
swabs for polymerase chain reaction-based biomarker as-
says. Environmental Health Perspectives 107:517–520
Weinberg CR (1999) Allowing for missing parents in genetic
studies of case-parent triads. Am J Hum Genet 64:1186–
1193
Weinberg CR,Wilcox AJ, Lie RT (1998) A log-linear approach
to case-parent-triad data: assessing the effects of disease
genes that act either directly or through maternal effects and
that may be subject to parental imprinting. Am JHumGenet
62:969–978
Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H,
Molloy AM, Weir DG, Shields DC, Scott JM (1995) A ge-
netic defect in 5,10 methylenetetrahydrofolate reductase in
neural tube defects. QJM 88:763–766
Wilcox AJ, Weinberg CR, Lie RT (1998) Distinquishing the
effects of maternal and offspring genes through studies of
“case-parent triads.” Am J Epidemiol 148:893–901
Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H,
Gravel RA, Rozen R (1999) A common variant of methi-
onine synthase reductase combined with low cobalamin (vi-
tamin B12) increases risk for spina bifida. Mol Genet Metab
67:317–323
